Kyoto University Innovation Capital — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy.
BiotechHealthtechMedical DevicesEscondido, US
Masatoshi Hagiwara(Chief Scientific Officer, Director of the Board (founder of BTB Therapeutics Co., Ltd.))inTakashi Kiyoizumi(CEO, Director of the Board)inKenneth W. Locke(Chief Development Officer)in
RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.
BiotechDeep TechMedical Devices
Michael McCullar, PhD(Chief Executive Officer)James Ahlers(Chief Financial Officer)Marty Giedlin, PhD(Chief Technology Officer)Tony Hurley(Chief Technical Operations Officer)Steve Kanner, PhD(Chief Scientific Officer)
Co-investorsFast Track InitiativeGlobal BrainLG Technology VenturesOSAKA University Venture CapitalUTECAlumni Ventures+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




